Rossari Biotech Ltd

- No significant additional Capex planned for FY24 and the next two to three years; focus is on optimizing current assets and capacities. - Small Capex ongoing in the Animal Health and Nutrition (AHN) segment to set up a premix plant for vitamins, mineral mixes, and enzymes. - Capex also initiated in the agro space for scaling up silicone super wetters production. - FY24 and FY25 estimated Capex around Rs. 40-50 crore. - Overall strategy emphasizes growth mainly through business ramp-up and acquisitions rather than large capital investments. - Merger of subsidiaries (Tristar and Unitop) planned by 31st March 2024 to consolidate operations and improve efficiencies.

- Focus on growing HPPC segment (Home & Personal Care, Agro, Performance Chemicals) with healthy demand outlook for FY24. - Animal Health and Nutrition (AHN) segment targeted for highest percentage growth; expected to double revenue in 2-3 years with new premix plant and new products. - Exports growing rapidly with Rs.380 crore in FY23 vs Rs.264 crore last year, expected to continue increase. - Consolidation through mergers of subsidiaries (Tristar and Unitop) by March 31, 2024, aiming for operational efficiencies and growth. - Unitop and Tristar showed 20%+ YoY revenue growth in FY23 on a like-to-like basis, expected to maintain growth trajectory. - Targeting absolute EBITDA growth of 20-30% in FY24 with controlled expenses and no major Capex. - Volumes growth hard to quantify due to changing product mix but overall topline growth is the focus.

- Management projects 20% growth in EBITDA for FY24 over consolidated EBITDA of FY23. - Sunil Chari mentioned aiming for about 30% bottom-line growth in FY24. - No additional Capex planned for FY24, helping control depreciation and expenses. - Expected healthy demand outlook across HPPC (home, personal care, performance chemicals), agro, and animal health & nutrition (AHN) segments. - AHN segment, currently Rs.125 crore, is expected to see the highest percentage growth. - Consolidation of subsidiaries (Tristar fully owned, Unitop merger by March 2024) expected to streamline operations and improve profitability. - Focus on EBITDA absolute growth rather than percentage margins. - Confidence to double AHN revenue in the next 2-3 years, contributing positively to profits. - Export growth and product innovations like enzyme-based bio-surfactants are additional growth drivers.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Rossari Biotech Limited. However, some relevant insights related to business outlook include: - The company is confident in doubling revenue in the AHN (Animal Health Nutrition) business over the next 2-3 years. - Management is upbeat about introducing a new bio-based enzyme product as a surfactant, expected in a few months. - The overall business remains strong with a net cash position of Rs. 77 crore as of March 2023. - They expect growth and stable margins in FY24 driven by synergy benefits across subsidiaries and standalone business. - Utilization levels are around 50–55% across plants, indicating capacity for order growth. For detailed current or pending orderbook figures, the transcript does not provide specific numbers.

- No specific mention of any new fundraising through debt or equity in the transcript. - Interest cost for FY23 was Rs. 22.3 crore, partly due to consolidation accounting entries. - For FY24, interest cost is expected to decrease as loan amounts reduce (Rs. 74 crore loan, Rs. 20 crore working capital currently). - The company funded acquisition of an additional 16% stake in Tristar (Rs. 17 crore) through internal accruals, indicating use of internal funds rather than fresh fundraising. - Cash and cash equivalents stand at Rs. 69.8 crore (FY23), with net cash flow from operations being healthy at Rs. 152.4 crore. - Overall, the company emphasizes a strong balance sheet and internal accruals funding, with no direct indication of plans for new debt or equity issuance in the immediate future.